Akebia Therapeutics, Inc. (AKBA) shareholders
Close on Nov 17, 2026Market cap $110.95MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 19,219,819 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AKBA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 19,986,374 | 7.21% | $22.78M | +1,293,078 | 0.00% |
| Vanguard Capital Management LLC | 11,322,143 | 4.09% | $12.91M | +155,433 | 0.00% |
| Aqr Capital Management LLC | 9,151,524 | 3.30% | $10.43M | +7,358,904 | 0.00% |
| Geode Capital Management, LLC | 6,727,302 | 2.43% | $7.67M | +275,050 | 0.00% |
| State Street Corp | 5,390,853 | 1.95% | $6.15M | −6,223,153 | 0.00% |
| Jacobs Levy Equity Management, Inc | 4,273,026 | 1.54% | $4.87M | +3,843,357 | 0.02% |
| Acadian Asset Management LLC | 4,004,867 | 1.45% | $4.56M | +2,627,799 | 0.01% |
| Nantahala Capital Management, LLC | 4,000,000 | 1.44% | $4.56M | +2,000,000 | 0.08% |
| Goldman Sachs Group Inc | 3,689,167 | 1.33% | $4.21M | +86,340 | 0.00% |
| Millennium Management LLC | 3,196,605 | 1.15% | $3.64M | +811,892 | 0.00% |
| Vanguard Portfolio Management LLC | 2,533,977 | 0.91% | $2.89M | +318,536 | 0.00% |
| Two Sigma Investments, LP | 2,436,673 | 0.88% | $2.78M | +1,138,872 | 0.00% |
| Charles Schwab Investment Management Inc | 2,300,438 | 0.83% | $2.62M | +284,861 | 0.00% |
| Northern Trust Corp | 2,160,365 | 0.78% | $2.46M | +214,779 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,908,797 | 0.69% | $2.18M | +129,496 | 0.00% |
| FMR LLC | 1,871,059 | 0.68% | $2.13M | +535,731 | 0.00% |
| Qube Research & Technologies Ltd | 1,779,707 | 0.64% | $2.03M | −615,508 | 0.00% |
| Citadel Advisors LLC | 1,717,659 | 0.62% | $1.96M | +327,592 | 0.00% |
| UBS Group AG | 1,374,950 | 0.50% | $1.57M | +605,479 | 0.00% |
| Renaissance Technologies LLC | 1,223,963 | 0.44% | $1.40M | −609,165 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 170 | 110M | 39.7% | 37 / 69 | 33 / 36 | 29M | 20M |
| Q1 2026 | 171 | 102M | 36.7% | 37 / 41 | 53 / 29 | 24M | 24M |
| Q4 2025 | 166 | 118M | 42.7% | 23 / 63 | 48 / 32 | 18M | 25M |
| Q3 2025 | 177 | 125M | 45.0% | 40 / 67 | 39 / 18 | 28M | 12M |
| Q2 2025 | 157 | 108M | 39.1% | 32 / 77 | 23 / 18 | 28M | 15M |
| Q1 2025 | 143 | 96M | 34.5% | 30 / 63 | 26 / 5 | 35M | 1M |
| Q4 2024 | 121 | 68M | 24.6% | 24 / 47 | 19 / 15 | 11M | 2M |
| Q3 2024 | 114 | 60M | 21.5% | 27 / 31 | 25 / 15 | 21M | 6M |
| Q2 2024 | 103 | 56M | 20.3% | 23 / 31 | 23 / 32 | 19M | 21M |
| Q1 2024 | 114 | 59M | 21.2% | 40 / 27 | 24 / 13 | 11M | 8M |
| Q4 2023 | 87 | 55M | 20.0% | 15 / 23 | 20 / 4 | 7M | 2M |
| Q3 2023 | 76 | 51M | 18.4% | 7 / 19 | 21 / 10 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
136 funds held AKBA in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AKBA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7,912,283 | 2.86% | $9.02M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,792,653 | 2.45% | $7.74M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 3,164,884 | 1.14% | $3.61M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,807,664 | 1.01% | $3.71M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,169,896 | 0.78% | $2.47M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1,638,117 | 0.59% | $1.87M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,397,714 | 0.50% | $1.43M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,298,780 | 0.47% | $1.32M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,262,655 | 0.46% | $1.29M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 868,716 | 0.31% | $990.34K | 0.07% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 751,608 | 0.27% | $766.64K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 631,828 | 0.23% | $834.01K | 0.01% | Jul 31, 2026 |
| iShares U.S. Small-Cap Equity Factor ETF | 613,144 | 0.22% | $809.35K | 0.02% | Jul 31, 2026 |
| AQR Small Cap Multi-Style Fund | 566,557 | 0.20% | $645.87K | 0.17% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 466,701 | 0.17% | $476.04K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John P. Butler | CEO and President, Director | 3,878,492 | 1.40% | Aug 10, 2026 |
| Erik Ostrowski | SVP, CFO, CBO & Treasurer | 616,616 | 0.22% | Jul 1, 2026 |
| Steven Keith Burke | SVP, Chief Medical Officer | 948,432 | 0.34% | Feb 4, 2026 |
| Nicholas Grund | Chief Commercial Officer | 561,750 | 0.20% | Feb 4, 2026 |
| Richard C. Malabre | SVP, Chief Accounting Officer | 312,772 | 0.11% | Feb 4, 2026 |
| Carolyn M. Rucci | SVP, Chief Legal Officer | 588,378 | 0.21% | Feb 4, 2026 |
| Leanne M. Zumwalt | Director | 145,100 | 0.05% | Jun 22, 2026 |
| Cynthia Smith | Director | 196,633 | 0.07% | Jun 22, 2026 |
| Adrian Adams | Director | 236,200 | 0.09% | Jun 22, 2026 |
| Michael W. Rogers | Director | 197,429 | 0.07% | Jun 22, 2026 |
| Myles Wolf | Director | 169,081 | 0.06% | Jun 22, 2026 |
| Ron Frieson | Director | 165,200 | 0.06% | Jun 22, 2026 |
| Philip J. Vickers | Director | – | – | Apr 3, 2026 |
| Steven C. Gilman | Director | 152,830 | 0.06% | Jun 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John P. Butler CEO and President, Director | Aug 6, 2026 | Option exercise | +350,000 | $0.63 | $220.50K | 3,718,564 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jun 29, 2026 | Sale(10b5-1 plan) | −56,019 | $1.11 | $62.18K | 616,616 |
| Adrian Adams Director | Jun 17, 2026 | Award | +35,700 | – | – | 236,200 |
| Cynthia Smith Director | Jun 17, 2026 | Award | +35,700 | – | – | 196,633 |
| Leanne M. Zumwalt Director | Jun 17, 2026 | Award | +35,700 | – | – | 145,100 |
| Ron Frieson Director | Jun 17, 2026 | Award | +35,700 | – | – | 165,200 |
| Michael W. Rogers Director | Jun 17, 2026 | Award | +35,700 | – | – | 197,429 |
| Myles Wolf Director | Jun 17, 2026 | Award | +35,700 | – | – | 169,081 |
| John P. Butler CEO and President, Director | Mar 4, 2026 | Buy | +69,270 | $1.25 | $86.59K | 3,367,064 |
| Richard C. Malabre SVP, Chief Accounting Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −36,142 | $1.39 | $50.24K | 312,772 |
| Richard C. Malabre SVP, Chief Accounting Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −13,382 | $1.39 | $18.60K | 299,390 |
| Nicholas Grund Chief Commercial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −31,244 | $1.39 | $43.43K | 561,750 |
| Nicholas Grund Chief Commercial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −53,585 | $1.39 | $74.48K | 592,994 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −20,701 | $1.39 | $28.77K | 948,432 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −21,582 | $1.39 | $30.00K | 994,508 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −25,375 | $1.39 | $35.27K | 969,133 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −46,660 | $1.39 | $64.86K | 3,417,189 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −96,065 | $1.39 | $133.53K | 3,321,124 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −114,891 | $1.39 | $159.70K | 3,206,233 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −83,689 | $1.39 | $116.33K | 3,297,794 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Award | +175,250 | $1.41 | $247.10K | 3,381,483 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Feb 2, 2026 | Sale(10b5-1 plan) | −34,951 | $1.39 | $48.58K | 672,635 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −27,544 | $1.39 | $38.29K | 588,378 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −25,382 | $1.39 | $35.28K | 615,922 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −16,846 | $1.39 | $23.42K | 641,304 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jan 30, 2026 | Award | +79,000 | – | – | 348,914 |
| John P. Butler CEO and President, Director | Jan 30, 2026 | Award | +743,000 | – | – | 3,463,849 |
| Steven Keith Burke SVP, Chief Medical Officer | Jan 30, 2026 | Award | +204,000 | – | – | 1,016,090 |
| Nicholas Grund Chief Commercial Officer | Jan 30, 2026 | Award | +204,000 | – | – | 646,579 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Jan 30, 2026 | Award | +190,000 | – | – | 658,150 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jan 30, 2026 | Award | +204,000 | – | – | 707,586 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jun 30, 2025 | Sale(10b5-1 plan) | −41,314 | $3.67 | $151.62K | 503,586 |
| Michael W. Rogers Director | Jun 10, 2025 | Award | +35,700 | – | – | 161,729 |
| Ron Frieson Director | Jun 10, 2025 | Award | +35,700 | – | – | 129,500 |
| Steven C. Gilman Director | Jun 10, 2025 | Award | +35,700 | – | – | 152,830 |
| Leanne M. Zumwalt Director | Jun 10, 2025 | Award | +35,700 | – | – | 109,400 |
| Cynthia Smith Director | Jun 10, 2025 | Award | +35,700 | – | – | 160,933 |
| Myles Wolf Director | Jun 10, 2025 | Award | +35,700 | – | – | 133,381 |
| Adrian Adams Director | Jun 10, 2025 | Award | +35,700 | – | – | 200,500 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jun 9, 2025 | Option exercise | +15,000 | $1.68 | $25.20K | 281,914 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jun 9, 2025 | Sale(10b5-1 plan) | −15,000 | $4.01 | $60.15K | 266,914 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jun 4, 2025 | Sale(10b5-1 plan) | −13,334 | $3.53 | $47.07K | 266,914 |
| John P. Butler CEO and President, Director | Mar 3, 2025 | Sale(10b5-1 plan) | −46,409 | $1.83 | $84.93K | 2,557,921 |
| Steven Keith Burke SVP, Chief Medical Officer | Mar 3, 2025 | Sale(10b5-1 plan) | −7,144 | $1.83 | $13.07K | 809,090 |
| Richard C. Malabre SVP, Chief Accounting Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −30,202 | $2.10 | $63.42K | 280,248 |
| Nicholas Grund Chief Commercial Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −55,621 | $2.10 | $116.80K | 442,579 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −27,236 | $2.10 | $57.20K | 816,234 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −23,270 | $2.10 | $48.87K | 843,470 |
| John P. Butler CEO and President, Director | Feb 3, 2025 | Sale(10b5-1 plan) | −97,982 | $2.10 | $205.76K | 2,604,330 |
| John P. Butler CEO and President, Director | Feb 3, 2025 | Sale(10b5-1 plan) | −46,268 | $2.10 | $97.16K | 2,702,312 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jan 31, 2025 | Award | +85,000 | – | – | 310,450 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jan 31, 2025 | Award | +194,900 | – | – | 544,900 |
| Nicholas Grund Chief Commercial Officer | Jan 31, 2025 | Award | +194,900 | – | – | 498,200 |
| Steven Keith Burke SVP, Chief Medical Officer | Jan 31, 2025 | Award | +194,900 | – | – | 866,740 |
| John P. Butler CEO and President, Director | Jan 31, 2025 | Award | +701,000 | – | – | 2,748,580 |
| Ron Frieson Director | Jan 17, 2025 | Option exercise | +20,100 | $0.45 | $9.05K | 93,800 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jun 28, 2024 | Award | +350,000 | – | – | 350,000 |
| Steven C. Gilman Director | Jun 6, 2024 | Award | +30,000 | – | – | 117,130 |
| Ron Frieson Director | Jun 6, 2024 | Award | +30,000 | – | – | 73,700 |
| Leanne M. Zumwalt Director | Jun 6, 2024 | Award | +30,000 | – | – | 73,700 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Akebia Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 151,739 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Erik Ostrowski Officer | Jun 29, 2026 | 56,019 | $62.22K | Jun 29, 2026 | Vesting of restricted stock unit |
| Carolyn M. Rucci Officer | Feb 2, 2026 | 69,772 | $97.30K | Feb 2, 2026 | Restricted Stock |
| John P. Butler Officer | Feb 2, 2026 | 341,305 | $475.95K | Feb 2, 2026 | Restricted Stock |
| Steven Keith Burke Officer | Feb 2, 2026 | 67,658 | $94.35K | Feb 2, 2026 | Restricted Stock |
| Nicholas Grund Officer | Feb 2, 2026 | 84,829 | $118.29K | Feb 2, 2026 | Restricted Stock |
| Erik Ostrowski Officer | Feb 2, 2026 | 34,951 | $48.74K | Feb 2, 2026 | Restricted Stock |
| Erik Ostrowski Officer | Jun 30, 2025 | 41,314 | $151.62K | Jun 30, 2025 | Restricted Stock |
| Steven Keith Burke Officer | Mar 3, 2025 | 7,144 | $13.09K | Mar 3, 2025 | Restricted Stock |
| John P. Butler Officer, Director | Mar 3, 2025 | 46,409 | $85.01K | Mar 3, 2025 | Restricted Stock |
| Steven Keith Burke Officer | Feb 3, 2025 | 50,506 | $106.30K | Feb 3, 2025 | Restricted Stock |
| John P. Butler Officer, Director | Feb 3, 2025 | 144,250 | $303.59K | Feb 3, 2025 | Restricted Stock |
| Nicholas Grund Officer | Feb 3, 2025 | 55,621 | $117.06K | Feb 3, 2025 | Restricted Stock |
| Nicole R. Hadas Officer | May 13, 2024 | 12,016 | $15.11K | May 13, 2024 | Restricted Stock |
| Michel Dahan Officer | May 13, 2024 | 34,840 | $43.82K | May 13, 2024 | Restricted Stock |
| Michel Dahan Officer | Feb 29, 2024 | 8,661 | $13.65K | Feb 29, 2024 | Restricted Stock |
See a number that looks wrong?